Limits...
Immunomodulatory effects of Newcastle disease virus AF2240 strain on human peripheral blood mononuclear cells.

Lam HY, Yusoff K, Yeap SK, Subramani T, Abd-Aziz S, Omar AR, Alitheen NB - Int J Med Sci (2014)

Bottom Line: Interestingly, the percentage of cells with activating markers CD16 and CD56 were increased significantly.Human PBMC treated with NDV titer 8 HAU was found to stimulate the highest level of cytokine production including interferon-γ, interleukin-2 and interleukin-12.The release of these proteins contributes to the antitumor effect of PBMC against MCF-7 breast cancer cells.

View Article: PubMed Central - PubMed

Affiliation: 1. Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.

ABSTRACT
Immunotherapy has raised the attention of many scientists because it hold promise to be an attractive therapeutic strategy to treat a number of disorders. In this study, the immunomodulatory effects of low titers of Newcastle disease virus (NDV) AF2240 on human peripheral blood mononuclear cells (PBMC) were analyzed. We evaluated cytokine secretion and PBMC activation by cell proliferation assay, immunophenotyping and enzyme linked immunosorbent assay. The proliferation of the human PBMC was measured to be 28.5% and 36.5% upon treatment with 8 hemaglutinin unit (HAU) and 2 HAU of NDV respectively. Interestingly, the percentage of cells with activating markers CD16 and CD56 were increased significantly. Furthermore, the intracellular perforin and granzyme levels were also increased upon virus infection. Human PBMC treated with NDV titer 8 HAU was found to stimulate the highest level of cytokine production including interferon-γ, interleukin-2 and interleukin-12. The release of these proteins contributes to the antitumor effect of PBMC against MCF-7 breast cancer cells. Based on the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay, activated human PBMC showed high cytolytic efficiency towards human breast tumor cells. In summary, NDV was able to stimulate PBMC proliferation, cytokine secretion and cytolytic activity.

Show MeSH

Related in: MedlinePlus

ELISA result showed the level of interleukin-12 released from the human PBMC after treated by NDV at different titers.The values were the means ± SE of three independent experiment. The differences between the control group and treated group were determined by one-way ANOVA. (* p < 0.05).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4196125&req=5

Figure 4: ELISA result showed the level of interleukin-12 released from the human PBMC after treated by NDV at different titers.The values were the means ± SE of three independent experiment. The differences between the control group and treated group were determined by one-way ANOVA. (* p < 0.05).

Mentions: The level of IL-2 was also determined as it has the ability to augment the immune functions of NK cells such as T lymphocytes and macrophages. Figure 3 shows the time dependent increase of IL-2 levels by human PBMC after NDV induction. The highest IL-2 level was obtained after 72 hours for both treatment groups. The level of IL-12 increased significantly (p< 0.05) after being cultured with NDV titer 8 HAU and 2 HAU for all 24, 48 and 72 hours except treatment time 72 hours for treatment group with titer 2 HAU (Figure 4). We speculate that IL-12 plays a role in enhancing cytotoxicity of human immune system against cancer cell. Taken together, the release of augmented levels of cytokines indicated the activation status of human PBMC. These results complemented with the findings by Carlens et al. 15 and Ortaldo et al. 16 who reported that cytokines, such as IFN-γ, IL-2 and IL-12 might enhance NK cell proliferation and activities.


Immunomodulatory effects of Newcastle disease virus AF2240 strain on human peripheral blood mononuclear cells.

Lam HY, Yusoff K, Yeap SK, Subramani T, Abd-Aziz S, Omar AR, Alitheen NB - Int J Med Sci (2014)

ELISA result showed the level of interleukin-12 released from the human PBMC after treated by NDV at different titers.The values were the means ± SE of three independent experiment. The differences between the control group and treated group were determined by one-way ANOVA. (* p < 0.05).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4196125&req=5

Figure 4: ELISA result showed the level of interleukin-12 released from the human PBMC after treated by NDV at different titers.The values were the means ± SE of three independent experiment. The differences between the control group and treated group were determined by one-way ANOVA. (* p < 0.05).
Mentions: The level of IL-2 was also determined as it has the ability to augment the immune functions of NK cells such as T lymphocytes and macrophages. Figure 3 shows the time dependent increase of IL-2 levels by human PBMC after NDV induction. The highest IL-2 level was obtained after 72 hours for both treatment groups. The level of IL-12 increased significantly (p< 0.05) after being cultured with NDV titer 8 HAU and 2 HAU for all 24, 48 and 72 hours except treatment time 72 hours for treatment group with titer 2 HAU (Figure 4). We speculate that IL-12 plays a role in enhancing cytotoxicity of human immune system against cancer cell. Taken together, the release of augmented levels of cytokines indicated the activation status of human PBMC. These results complemented with the findings by Carlens et al. 15 and Ortaldo et al. 16 who reported that cytokines, such as IFN-γ, IL-2 and IL-12 might enhance NK cell proliferation and activities.

Bottom Line: Interestingly, the percentage of cells with activating markers CD16 and CD56 were increased significantly.Human PBMC treated with NDV titer 8 HAU was found to stimulate the highest level of cytokine production including interferon-γ, interleukin-2 and interleukin-12.The release of these proteins contributes to the antitumor effect of PBMC against MCF-7 breast cancer cells.

View Article: PubMed Central - PubMed

Affiliation: 1. Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.

ABSTRACT
Immunotherapy has raised the attention of many scientists because it hold promise to be an attractive therapeutic strategy to treat a number of disorders. In this study, the immunomodulatory effects of low titers of Newcastle disease virus (NDV) AF2240 on human peripheral blood mononuclear cells (PBMC) were analyzed. We evaluated cytokine secretion and PBMC activation by cell proliferation assay, immunophenotyping and enzyme linked immunosorbent assay. The proliferation of the human PBMC was measured to be 28.5% and 36.5% upon treatment with 8 hemaglutinin unit (HAU) and 2 HAU of NDV respectively. Interestingly, the percentage of cells with activating markers CD16 and CD56 were increased significantly. Furthermore, the intracellular perforin and granzyme levels were also increased upon virus infection. Human PBMC treated with NDV titer 8 HAU was found to stimulate the highest level of cytokine production including interferon-γ, interleukin-2 and interleukin-12. The release of these proteins contributes to the antitumor effect of PBMC against MCF-7 breast cancer cells. Based on the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay, activated human PBMC showed high cytolytic efficiency towards human breast tumor cells. In summary, NDV was able to stimulate PBMC proliferation, cytokine secretion and cytolytic activity.

Show MeSH
Related in: MedlinePlus